Acute Porphyria Drugs

Monograph

J05AF08 - Adefovir Dipivoxil
Propably not porphyrinogenic
PNP

Rationale
Probably no significant CYP-interactions.
Chemical description
Oral prodrug to adefovir that is an acyclic nucleotide phosphonate analogue, which intracellularly is converted to adefovir diphosphate, inibitor of viral polymerases. Used, tabl 10 mg/d, in the treatment of chronic hepatitis B in adults with signs of liver engagement. The risk for CYP related drug interactions is considered low.
Similar drugs
Explore alternative drugs in similar therapeutic classes J05A / J05AF or go back.
References
Tradenames

Hepsera Hepsera Hepsera Hepsera Hepsera Hepsera Hepsera Hepsera Adefovir dipivoxil ยท Hepsera Adefovir dipivoxil
In cooperation with IpNet
© NAPOS 2025
An unhandled error has occurred. Reload ๐Ÿ—™